Protalix BioTherapeutics, Inc.
- Market cap
- $216.74M
- 52w range
- $1.60 - $3.19
- Beta
- 0.02
- Sector
- Healthcare
- Data quality
- 96/100
- P/E ratio
- 11.7x
- Forward P/E
- 4.3x
- Moat score
- 74/100
- Return on equity
- 31.2%
- Profit margin
- 23.5%
- Debt / equity
- 0.13
- Revenue growth
- +27.1%
- Analyst target
- $11.00
- Target upside
- +310.4%
- Analysts
- 2
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Valuation
Derived from filed metrics · High confidence (96% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).